Search results for "VINO"

showing 10 items of 186 documents

Oral vinorelbine may not induce acute pain at the tumor site.

2006

Oncologymedicine.medical_specialtybusiness.industryTreatment outcomeAdministration OralPainVinorelbineVinorelbineVinblastineTumor siteAntineoplastic Agents PhytogenicVinblastineAnesthesiology and Pain MedicineTreatment OutcomeInternal medicineNeoplasmsmedicineHumansNeurology (clinical)businessGeneral NursingAcute painmedicine.drugPain Measurement
researchProduct

Recensione al testo di ARTURO DE VIVO, Frammenti di discorsi ovidiani, Napoli, Loffredo, 2011, pp. 157

2012

Ovidio Seneca Calvino Virgilio poesia epica ed elegiaca innovazione.
researchProduct

INSTRUMENTOS DE PROMOCIÓN DE LOS VINOS EN LOS RESTAURANTES DE ALTO NIVEL / INSTRUMENTS FOR WINE PROMOTION IN HIGH LEVEL RESTAURANTS

2009

En los últimos años, la comercialización de vinos está adquiriendo un peso creciente en los establecimientos de restauración. El aumento en la complejidad de la oferta de vinos determina que la elección del consumidor esté condicionada por la oferta presente en la carta y por la influencia del personal de sala. El objetivo del presente trabajo es identificar y caracterizar los instrumentos relevantes de promoción de los vinos que utilizan los restaurantes, en función de la presencia de personal formado en vinos. Como resultado de un estudio realizado para una muestra de restaurantes de alto nivel, observamos que el contenido y el diseño de la carta de vinos se encuentran en granmedida condi…

Promoción Vino Hostelería Promotion Wine HospitalityInvestigaciones Europeas de Dirección y Economía de la Empresa
researchProduct

Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and…

2003

Abstract Purpose: we carried out a phase III randomized trial to compare vinorelbine–cisplatin regimen to gemcitabine–cisplatin regimen, and to a sequential administration of gemcitabine–ifosfamide followed by vinorelbine–cisplatin or the opposite sequence of vinorelbine–cisplatin followed by ifosfamide–gemcitabine according to the ‘worst drug rule’ hypothesis in patients with locally advanced unresectable stage IIIB or metastatic stage IV non-small cell lung cancer. The primary endpoint was survival parameters, while secondary endpoints included analysis of response rates and toxicity. Patients and methods: patients were randomized to receive: (a) gemcitabine 1000 mg/m2 on days 1, 8 and 15…

Pulmonary and Respiratory MedicineAdultMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsMaximum Tolerated DoseAdenocarcinomaVinorelbineVinblastineGastroenterologyDeoxycytidineInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansIfosfamideProspective StudiesLung cancerSurvival rateMesnaAgedIfosfamidebusiness.industryVinorelbineMiddle Agedmedicine.diseaseInterim analysisGemcitabineGemcitabineSurgerySurvival RateRegimenTreatment OutcomeOncologyCarcinoma Squamous CellDisease ProgressionCarcinoma Large CellFemaleCisplatinbusinessmedicine.drugLung cancer (Amsterdam, Netherlands)
researchProduct

Gemcitabine plus vinorelbine in stage IIIB or IV non-small cell lung cancer (NSCLC): A multicentre phase II clinical trial

2001

Abstract A phase II study in patients with stage IIIB/IV non-small cell lung cancer (NSCLC) was carried out to evaluate the clinical activity and toxicity of the chemotherapeutic combination of gemcitabine+vinorelbine (GEM/VNR). Forty-five patients (40 male, 5 female) with a median age of 67 years (range 37–73) and a median ECOG performance status of 1 (range 0–2) were enrolled into the trial. Twenty patients had stage IIIB (two positive supraclavicular nodes and 20 cytologically positive pleural effusion), and 25 had stage IV NSCLC. GEM 1000 mg/m 2 diluted in 250 cc 3 of normal saline was administered iv on days 1, 8, and 15, while VNR was given 30 mg/m 2 on days 1 and 8 every 4 weeks. The…

Pulmonary and Respiratory MedicineAdultMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsNeutropeniaPleural effusionmedicine.drug_classnon-small cell lung cancer (NSCLC)Phases of clinical researchNeutropeniaVinorelbineVinblastineGastroenterologyAntimetaboliteDeoxycytidineInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansInfusions IntravenousAgedbusiness.industryVinorelbineMiddle Agedmedicine.diseaseSurvival AnalysisGemcitabineGemcitabineSurgeryRegimenTreatment OutcomeOncologyInjections IntravenousFemalebusinessmedicine.drug
researchProduct

Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: a prospective randomized s…

2002

Abstract Purpose: To compare a regimen of vinorelbine and cisplatin (VC) to the combination of mitomycin, vindesine, and cisplatin (MVP) in patients with stage IIIB or stage IV non-small cell lung cancer (NSCLC). The main endpoits were analysis of objective response rates, toxicity, time to progression, and overall survival. Patients and methods: 247 eligible patients were randomized to receive (a) vinorelbine 25 mg/m 2 intravenous bolus on days 1and 8 plus cisplatin 100 mg/m 2 on day 1 every 4 weeks, or (b) mitomycin c 8 mg/m 2 i.v. on day 1, vindesine 3 mg/m 2 i.v. on days 1, 8, 15 and 22, plus cisplatin 100 mg/m 2 on day 1 every 4 weeks. In subsequent cycles vindesine was given every oth…

Pulmonary and Respiratory MedicineAdultMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsVindesinemedicine.medical_treatmentMitomycinVinorelbineVinblastineGastroenterologyDisease-Free SurvivalInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansProspective StudiesInfusions IntravenousAgedNeoplasm StagingCisplatinChemotherapyPerformance statusDose-Response Relationship Drugbusiness.industryMitomycin CVinorelbineMiddle Agedmedicine.diseaseSurgerySurvival RateRegimenTreatment OutcomeOncologyDisease ProgressionVindesineFemaleCisplatinbusinessProgressive diseasemedicine.drugLung cancer (Amsterdam, Netherlands)
researchProduct

Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients

2009

Abstract Background Doublet chemotherapy is more effective than single-agent as first line treatment of advanced non-small-cell lung cancer (NSCLC). No reliable information instead is available on the effect of doublets in second line treatment. The aim of DISTAL-2 study was to compare two doublets containing docetaxel with single agent docetaxel as second line treatment of patients with NSCLC (ClinicalTrials.gov id.:. NCT00345059 ). Methods NSCLC patients, aged 2 on days 1, 8, 15 q 4 weeks); arm B, weekly docetaxel (30 mg/m 2 on days 1, 8, 15) plus gemcitabine (800 mg/m 2 on days 1, 8 q 4 weeks) or plus vinorelbine (20 mg/m 2 on days 1, 8 q 4 weeks) depending on which of the two had been u…

Pulmonary and Respiratory MedicineCancer Researchmedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentUrologyCombination chemotherapymedicine.diseaseVinorelbineGemcitabineSurgerylaw.inventionCapecitabineOncologyDocetaxelRandomized controlled triallawmedicineLung cancerbusinessmedicine.drugLung Cancer
researchProduct

LA GESTIONE DEL VIGNETO SICILIANO

2008

QUALITA'UVA DA VINOTECNICHE COLTURALI
researchProduct

Davide Savio, "Il mondo si legge all’incontrario. La materia cavalleresca nel Novecento"

2020

Recensione a Davide Savio,Il mondo si legge all’incontrario. La materia cavalleresca nel Novecento (Interlinea, 2020)

Romanzo cavalleresco Calvino Bufalino Ariosto Novecento Davide Savio OblioSettore L-FIL-LET/11 - Letteratura Italiana Contemporanea
researchProduct

"Non è in crisi il romanzo borghese": una polemica degli anni Sessanta

2018

26 marzo 1965: su «Paese Sera-Libri» esce la trascrizione, mai più riedita, di una delle svariate tavole rotonde organizzate dal giornale in quegli anni, intitolata Requiem per il romanzo?: a cui hanno partecipato Alberto Arbasino, Francesco Leonetti, Alberto Moravia, Pier Paolo Pasolini, Edoardo Sanguineti, e, in veste di coordinatore, Armando Vitelli (fondatore e curatore del supplemento, con Piero Dallamano). La ripubblichiamo qui, insieme ad altri due pezzi di poco successivi, rispettivamente di Italo Calvino e di Vitelli stesso, che come vedremo le si agganciano.

Romanzolcsh:P101-410MoraviaSettore L-FIL-LET/14 - Critica Letteraria E Letterature Comparatelcsh:Translating and interpretinglcsh:Geography. Anthropology. RecreationRomanzo; Crisi; Arbasino; Pasolini; Moravia; Sanguineti; Vitelli; Calvinolcsh:P306-310Sanguinetilcsh:Language. Linguistic theory. Comparative grammarCrisislcsh:GCrisiVitelliPasoliniArbasinoCalvinoNovel
researchProduct